Ellen Matloff, MS, CGC is the President and CEO of My Gene Counsel. Ellen is the founder and former director of the Cancer Genetic Counseling Program at Yale School of Medicine.
Ellen has authored more than 50 scientific publications in the field, is an established educator, lecturer and media spokesperson and has received national awards for her ongoing patient advocacy efforts. She is an outspoken patient advocate in many areas, most notably as a plantiff in the 2013 BRCA gene patent case that went before the Supreme Court in 2013. This decision has led to drastically lower prices of genetic testing, making it possible for more patients to afford this technology.
As genetic testing became more common and also more complex, she served as the senior author on several publications documenting national errors in the misinterpretation of genetic test results. From these experiences, Ellen created My Gene Counsel and its associated digital tools that can be used in parallel with genetic testing to help ensure that results are used accurately and effectively.
Danielle Bonadies, MS, CGC is the Director of the Cancer Genetics Division of My Gene Counsel. She is responsible for the development of cancer-based content that populates the My Gene Counsel portal.
Before joining My Gene Counsel, Danielle served as the Assistant Director of the Cancer Genetic Counseling Program at Yale School of Medicine. She practiced as a clinical genetic counselor for over a decade, designed and ran several interactive, on-line patient education and communication sites, and was involved in the cancer genetics education of thousands of patients, clinicians and students.
Danielle has co-authored multiple book chapters and articles in genetic counseling and testing. She was involved in several seminal papers that document the high rate of result misinterpretation amongst clinicians ordering genetic testing. Her publications include work that helps understand the viewpoint of genetic counselors and physicians on a wide range of complex decisions associated with cancer genetic testing. Other publications focus on the informational needs of individuals with hereditary predispositions during decision making periods.
Danielle’s strong clinical, research and advocacy background illustrate her ongoing commitment to the field of hereditary cancers. She brings this dedication and leadership to the My Gene Counsel team.
Shyam Deval serves as the Chief Technology Officer (CTO) of My Gene Counsel. Shyam has been working in the healthcare technology space for eleven years, with extensive experience in the articulation, design, creation, launch, and management of mobile and web health applications. Shyam has past experiences in a Technology leadership role with both healthcare start-ups and larger organizations in Healthcare delivery and Biotech, Technology Products and Education domains. Shyam has been a programmer, data architect, project and program manager, product strategist, and educator in his over 20-year career.
Shyam spent four years as the President at Boston Technology Corporation (BTC) – one of the fastest growing healthcare technology companies in Boston. Shyam managed all of BTC’s healthcare technology offerings and clients, which included multiple Healthcare start-ups, large provider organizations, Universities and FDA. As part of his work with BTC, Shyam participated as the technical liaison in several successful initiatives focused on the use of technology to improve patient collaboration, research and care delivery.
Kira Dineen is the Communication Lead of My Gene Counsel. In this role she develops strategies to establish My Gene Counsel’s thought leadership platform and fosters engagement around consumer advocacy and education through online media. Kira brings 5 years of online media experience in the fields of digital marketing, social media, blogging and podcasting/radio.
She is passionate about advocating for the rare disease community and has worked collaboratively with the National Organization for Rare Disorders to provide education and raise awareness.
Kira received her Bachelor's of Science degree in Diagnostic Genetic Sciences with a concentration in Cytogenetics at the University of Connecticut. She hosts and produces a podcast/radio show, DNA Today, which educates the public on genetics and has been nominated in the 2015 and 2016 Podcast Awards.
Vincent T. DeVita, Jr., MD, FACP, FASCO, FAACR, serves and an advisor and Board member of My Gene Counsel. He is the Amy and Joseph Perella Professor of Medicine and Professor of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT. While Dr. DeVita was at the National Cancer Institute (NCI), he developed combination chemotherapy programs that ultimately led to an effective regimen (MOPP) of curative chemotherapy of Hodgkin's disease and diffuse large B-cell lymphomas. In 1972, DeVita received the Albert and Mary Lasker Medical Research Award for his contribution to the cure of Hodgkin's disease. He was elected to the National Academy of Medicine in 1974. In 1980, he was appointed by the President of the United States as Director of the NCI and the National Cancer Program. In 1988, DeVita joined Memorial Sloan-Kettering Cancer Center as Physician-in-Chief. He served as Professor of Medicine at Cornell University School of Medicine until 1993. He served as the Director of Yale Cancer Center from 1993 to 2003. In 2002, he was elected to the European Academy of Sciences for his outstanding and lasting contribution to cancer research and medical education. DeVita held the position of President of the American Cancer Society in 2012-13. He is one of three editors of Cancer: Principles & Practice of Oncology, a comprehensive textbook in the field of cancer medicine and author of the lay book The Death of Cancer written with his daughter Elizabeth DeVita Raeburn, a science writer, published in 2015.
David Cohen, MBA is an advisor and Board member of My Gene Counsel. He is a highly experienced business executive, entrepreneur and investor who has served as Executive VP of Standard Oil of Connecticut, Inc. for the past 22 years. David has also founded a number of highly successful ventures, including: Standard Security Systems, ResCom Energy, Moneo Technology Solutions and Standard Oil Ventures. He sits on the boards of multiple companies, including several in the health care arena.
Michael Driscoll, EMBA serves as a valued adviser and counsel to My Gene Counsel, a Connecticut Innovations portfolio company. In his role, he helps businesses successfully navigate engineering issues and assists CEOs with the growth of their businesses.
A seasoned operations professional, Michael served for more than 10 years as an executive officer in several capacities for Connecticut-based Winchester Electronics, a global leader in the design, development and deployment of interconnect technology. He was the company president from 2000 through 2006, and president and chief executive officer (CEO) from 2006 through 2010. Most recently, he served as the company’s chairman. Michael received a B.S. in Mechanical Engineering Technology from Roger Williams University, E.M.B.A. from University of New Haven, Executive Management and Leadership Training from Harvard Business School and Financial Management Certificate from The Wharton School of the University of Pennsylvania.
Rick Sowerby, MBA serves as a valued adviser and counsel to My Gene Counsel. He is a senior financial executive with hands-on operating experience and extensive, diversified business experience in both public and private equity sponsored environments. He has proven ability to lead organizations through startup, growth, and turnaround strategies. Rick earned his Bachelor of Science degree in Accounting from Penn State, his MBA from Duquesne University, Summa Cum Laude, and passed the CPA exam in 1992. Rick has been involved in green field startups, international joint ventures, numerous acquisitions, and divestitures of non-core businesses. In addition, he has worked in 10 different industries with Fortune 500, small cap, and family owned businesses. His experience includes working with four private equity groups including Bain Capital, Zell Chilmark, and Audax. He also worked for Pouschine Cook.
Rick possesses a strong process orientation as well as demonstrated skills in building top graded staffs, designing and guiding corporate, division, and plant finance functions through growth and change management. Rick has managed all financial functions including reporting, general ledger, cost accounting, credit, budgeting, planning, treasury, risk management, tax, debt & capital structure, and internal audit. Additionally, Rick managed IT, Human Resources, Legal, Supply Chain, and Investor Relations functions.